All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Psoriasis affecting high-impact or visible areas – such as the scalp, nails, genitals, or face – can significantly impair quality of life, even when overall skin involvement is limited. Despite this burden, many patients with moderate disease do not receive systemic therapy, and topical treatments often provide insufficient control. The EMBRACE trial (NCT03774875) was a phase IV, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of apremilast in patients with chronic plaque psoriasis involving at least one high-impact area, limited skin involvement (Psoriasis Area and Severity Index score ³3 and ≤10), and impaired quality of life. We have previously published the 16-week outcomes. Augustin et al. recently reported the 52-week results in Dermatology and Therapy, presenting long-term data on clinical response and quality-of-life outcomes.1
|
Key learnings |
At Week 52, 64.5% (98/152) of patients receiving continuous apremilast and 69.6% (48/69) of patients receiving placebo/apremilast achieved a DLQI response (≥4-point improvement from baseline). Mean itch NRS scores improved, with a change from baseline of −3.3 and −3.9 in the continuous apremilast and placebo/apremilast groups, respectively. |
At Week 52, PASI <3 was achieved in 37.5% (57/152) of patients receiving continuous apremilast and 50.7% (35/69) of patients receiving placebo/apremilast; mean BSA involvement was reduced from baseline by 32.0% and 49.9% in each treatment group, respectively. |
During apremilast exposure (N = 254), 85.4% of patients reported ≥1 TEAE; the most common were diarrhea (30.3%), headache (20.5%), nausea (17.7%), and nasopharyngitis (15.4%). Rates of serious TEAEs (7.1%) and TEAEs leading to withdrawal (12.2%) were low. |
Benefits of apremilast across quality of life, itch, pain, and skin outcomes were sustained through 52 weeks, with no new safety signals observed. These findings support its use as a long-term systemic option for psoriasis in high-impact areas. |
Abbreviations: BSA, body surface area; DLQI, Dermatology Life Quality Index; NRS, Numeric Rating Scale; PASI, Psoriasis Area and Severity Index; TEAE, treatment-emergent adverse event.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content